New biomarker tests could improve diagnostic accuracy in early Parkinson’s disease and even diagnose it before symptoms begin ...

MeiraGTx Holdings’ MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease (PD) ...

Some Diabetes Drugs Tied to Lower Risk of Dementia, Parkinson's Disease Sep. 18, 2024 — A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease ...

Parkinson's disease is generally considered a disease of late-middle age, with the average age of onset around 60. There are ...

Since his diagnosis last October, Scouten has been keeping a video journal to show how he lives with Parkinson's and to let ...

Gene therapy specialist Meiragtx Holdings plc got a market bump courtesy of newly released top-line data from its phase II bridging study in Parkinson’s disease. The six-month, three-arm randomized, ...

Every six minutes, someone in the U.S. is diagnosed with Parkinson's. These Parkinson's patients in the Cleveland area are ...

A tremor that won’t stop, slow movements, rigid muscles. They’re the classic signs of Parkinson’s disease that alert doctors ...

Shares in MeiraGTx rose after the company said it received positive data in a clinical bridging study of AAV-GAD for the treatment of Parkinson's disease. Shares were up nearly 14% in premarket ...

Shanghai Woli City hosted a Tai Chi event over the weekend, drawing a crowd of fans and professionals.

SAN DIEGO — According to the Parkinson's Foundation, nearly 90,000 Americans are diagnosed with the disease every year. In ...

Researchers from Nitrase Therapeutics Inc. recently presented preclinical findings on NTX-101, a murine chimeric antibody designed to specifically bind to nitrated tyrosine on α-synuclein (α-Syn). It ...